NL-OMON37099
Completed
Phase 2
A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure. - CRLX030A2201
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- ovartis
- Enrollment
- 10
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •\- Patients admitted to hospital or who require admission to hospital for management of acute heart failure with shortness of breath at rest or minimal exertion
- •\- stabilized within 2 days after admission
- •\- normal or elevated systolic blood pressure
- •\- elevated pulmonary capilary wedge pressure measured by Swan\-Ganz catheterization
Exclusion Criteria
- •\- severe renal impairment
- •\- significant liver impairment
- •\- significant lung impairment
- •\- significant heart valve dysfunction or arrythmias
- •\- myocardial infarction or acute coronary syndrome within th elast 45 days
Investigators
Similar Trials
Active, not recruiting
Phase 1
Effects of intravenous serelaxin infusion on micro- and macrovascular function in patients with coronary artery diseaseCoronary artery diseaseMedDRA version: 18.1 Level: PT Classification code 10011078 Term: Coronary artery disease System Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2012-001945-42-GBovartis Pharma Service AG58
Active, not recruiting
Not Applicable
Hemodynamic responses to intravenous RLX030 infusion in patients with acute heart failureAcute Heart FailureMedDRA version: 14.1Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-000833-35-PLovartis Pharma Services AG70
Active, not recruiting
Phase 1
A multicenter, randomized, double blind, parallel group, vehicle controlled, study of the safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 8 weeks in pediatric subjects (2 to 12 years of age) with mild to moderate plaque psoriasisPsoriasisTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2014-001744-38-BEGALDERMA R&D, LLC300
Active, not recruiting
Not Applicable
A multicenter, randomized, double blind, parallel group, vehicle controlled, study of the safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 8 weeks in pediatric subjects (2 to 12 years of age) with mild to moderate plaque psoriasisPsoriasisTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2014-001744-38-HUGALDERMA R&D, LLC300
Active, not recruiting
Phase 1
A multicenter, randomized, double blind, parallel group, vehicle controlled, study of the safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 8 weeks in pediatric subjects (2 to 12 years of age) with mild to moderate plaque psoriasisEUCTR2014-001744-38-ITGALDERMA RESEARCH & DEVELOPMENT, LLC300